[{"id":"solo2-iga01","name":"IGA 0/1 at Week 16","type":"PRIMARY","unit":"%","results":[{"notes":"36% vs 8% placebo","value":36,"arm_id":"dupixent-300-q2w-solo2","p_value":"<0.001","arm_name":"Dupilumab 300mg Q2W"},{"value":8,"arm_id":"placebo-solo2","arm_name":"Placebo"}],"timepoint":"Week 16","description":"Proportion of patients achieving Investigator Global Assessment score of 0 (clear) or 1 (almost clear) with ≥2-point reduction from baseline. Confirmatory study to SOLO 1."}]

SOLO 2 confirmed SOLO 1: 36% IGA 0/1 with dupilumab Q2W vs 8% placebo (p<0.001). EASI-75: 44% vs 12% (p<0.001). Together with SOLO 1, supported FDA approval for moderate-to-severe AD.

SOLO 2 (n=708, 16 weeks): Consistent with SOLO 1. Injection site reactions 12% vs 6%, conjunctivitis 9% vs 2%. Well-tolerated.

SOLO 2 is the confirmatory trial to SOLO 1. Results are consistent (36% vs 38% IGA 0/1). Together, they provided the registration package for AD approval.

Confirmatory companion study to SOLO 1. Identical design ensures reproducibility of IL-4Rα blockade in AD.